Hyderabad, Dec. 19
AUROBINDO Pharma Ltd (APL) has got six more of its ARV (anti retro viral) products onto the World Health Organisation (WHO) pre-qualification list.
The products included are: Efavirenz tablets - 600 mg; Lamivudine oral solution - 10 mg/ml; Lamivudine and Zidovudine tablets - 150/300 mg; Stavudine capsules - 30 mg; Stavudine capsules - 40 mg; and Zidovudine oral solution - 50 mg/5 ml.
Following this inclusion, the total number of the company's ARV products on WHO's pre-qualification list has gone up to 10, according to a press release from the company here today.
The products included previously are Zidovudine tablets 300 mg, Lamivudine tablets 150 mg, Lamivudine tablets 300 mg and Nevirapine tablets 200 mg. tablets.
This is the first time that Efavirenz tablets, an important first-line agent in the treatment of HIV/AIDS, are appearing on the WHO pre-qualification list.